Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 5/20 | 0.40 |
| ▸ | ARG1 | P05089 | 1/20 | 0.40 |
| ▸ | ARG2 | P78540 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 3/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | BHMT | Q93088 | 2/20 | 0.39 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2032831 | 1.00 | SLC7A5 (0.45) | SLC7A5SLC1A3SLC1A2SLC1A1KIF11 | |
| SCHEMBL476398 | 1.00 | SLC7A5 (0.45) | SLC7A5SLC1A3SLC1A2SLC1A1KIF11 | |
| SCHEMBL360209 | 1.00 | SLC7A5 (0.45) | SLC7A5SLC1A3SLC1A2SLC1A1KIF11 | |
| SCHEMBL28948326 | 0.80 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1KIF11 | |
| SCHEMBL13988062 | 0.80 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1KIF11 | |
| SCHEMBL6542263 | 0.80 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1KIF11 | |
| SCHEMBL13902860 | 0.80 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1KIF11 | |
| SCHEMBL6542267 | 0.80 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1KIF11 | |
| SCHEMBL160076 | 0.80 | SLC7A5 (0.42) | SLC7A5SLC1A3SLC1A2SLC1A1KIF11 | |
| SCHEMBL5490023 | 0.80 | SLC7A5 (0.42) | SLC7A5SLC1A3SLC1A2SLC1A1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 586 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299020-B2 | Antimicrobial peptides and methods of their use | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-10-30 | — | — | US | claimed |
| US-20110245152-A1 | ANTIBIOTIC ANTIMICROBIAL AGENTS AND METHODS OF THEIR USE | The Ohio State University Research Foundation a not-for-profit corporation | 2011-10-06 | — | — | US | claimed |
| EP-1915389-B1 | DIFFERENTIALLY PROTECTED ORTHOGONAL LANTHIONINE TECHNOLOGY | ORAGENICS INC (US) | 2011-06-08 | — | — | EP | claimed |
| EP-2069473-B1 | ANTIBIOTIC ANTIMICROBIAL AGENTS AND METHODS OF THEIR USE | UNIV OHIO STATE RES FOUND (US) | 2011-04-13 | — | — | EP | claimed |
| EP-1996217-B1 | NOVEL ANTIBIOTIC COMPOSITIONS | CAMBRIDGE ENTPR LTD (GB) | 2010-11-10 | — | — | EP | claimed |
| US-20100041613-A1 | NOVEL ANTIBIOTIC COMPOSITIONS | CAMBRIDGE ENTERPRISE LTD. (GB) | 2010-02-18 | — | — | US | claimed |
| EP-1996217-A4 | NOVEL ANTIBIOTIC COMPOSITIONS | INFLAZYME PHARM LTD (CA) | 2009-08-12 | — | — | EP | claimed |
| EP-2069473-A2 | ANTIBIOTIC ANTIMICROBIAL AGENTS AND METHODS OF THEIR USE | The Ohio State University Research Foundation (US) | 2009-06-17 | — | — | EP | claimed |
| EP-1750740-A4 | TREATMENT OF MEMBRANE-ASSOCIATED DISEASES AND DISORDERS USING LANTIBIOTIC CONTAINING COMPOSITIONS | MOLICHEM MEDICINES INC (US) | 2009-06-10 | — | — | EP | claimed |
| EP-1753445-A4 | TREATMENT OF OCULAR DISEASES AND DISORDERS USING LANTIBIOTIC COMPOSITIONS | MOLICHEM MEDICINES INC (US) | 2009-05-20 | — | — | EP | claimed |
| EP-0948535-A1 | NOVEL LANTHIONINE ANTIBIOTIC COMPOSITIONS AND METHODS | THE UAB RESEARCH FOUNDATION (US) | 1999-10-13 | — | — | EP | claimed |
| US-5914250-A | GENE WHICH CODES FOR MUTANT ANTIBIOTIC HAVING ISOLEUCINE SUBSTITUTED AT 4 POSITION OF AMINO ACID SEQUENCE | UNIVERSITY OF MARYLAND (US) | 1999-06-22 | — | — | US | claimed |
| US-5885811-A | LEADER SEQUENCE MAY BE USED TO INDUCE THE PRESENCE OF COVALENT BONDING SITES IN POLYPEPTIDES AND CAN BE EXPRESSED BY EITHER NATURALLY OCCURRING OR ARTIFICIAL MEANS | UNIVERSITY OF MARYLAND (US) | 1999-03-23 | — | — | US | claimed |
| US-5872001-A | DNA SEGMENTS CODES POLYPEPTIDES | UAB RESEARCH FOUNDATION (US) | 1999-02-16 | — | — | US | claimed |
| WO-1998017685-A9 | NOVEL LANTHIONINE ANTIBIOTIC COMPOSITIONS AND METHODS | — | 1998-08-13 | — | — | WO | claimed |
| WO-1998017685-A1 | NOVEL LANTHIONINE ANTIBIOTIC COMPOSITIONS AND METHODS | THE UAB RESEARCH FOUNDATION (US) | 1998-04-30 | — | — | WO | claimed |
| US-5650320-A | GENE EXPRESSION AND GENETIC ENGINEERING, PETIDE ANTIBIOTICS | UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION (US) | 1997-07-22 | — | — | US | claimed |
| US-4452782-A | IMMUNOPOTENTIATING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1984-06-05 | — | — | US | claimed |
| EP-0019072-B1 | PENTADECAPEPTIDE, PROCESS FOR THE PREPARATION THEREOF AND IMMUNOPOTENTIATING AGENT | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-09-14 | — | — | EP | claimed |
| EP-0019072-A1 | Pentadecapeptide, process for the preparation thereof and immunopotentiating agent | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-11-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041613-A1 | NOVEL ANTIBIOTIC COMPOSITIONS | MRPL21, NRDC, OTUB1 | SLC7A5 2031/4885SLC1A3 4747/4885SLC1A2 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.